This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Meet the global CMOs, CROs, suppliers and technology leaders who can accelerate your product to market

Register for your 1-day novel technology showcase pass today

March 12 Exhibit Hall Hours: 9:45 am – 1:30 pm

What's Included With Your Novel Technology Showcase Pass?

Bioprocessing decision makers and scientists working across cell line development, upstream/downstream processing, commercial manufacturing, analytics, viral safety and vaccines
Exhibitors representing global CMOs, CROs, suppliers and technology leaders who can help your company accelerate your product to market.
Peer-submitted scientific posters containing unpublished data across the entire spectrum of biopharmaceutical development & production.

Access Two Keynote Presentations from the Brightest Minds in Bioprocessing

[8:10am - 8:40am] 

The Transition from Protein-Based to Cell and Gene Therapy Products – Advantages, Surprises and Lessons Learned 

Uwe Gottschalk, Ph.D., Chief Scientific Officer at Lonza 

[8:40am - 9:10am] 

Genentech’s Evolve Initiative

Josefine Persson, Ph.D., Associate Director, Purification Development at Genentech 

Emerging & Innovative Technologies Panel Discussion

[10:25am - 12:25pm]

In this Emerging and Innovative Technology session, new technologies will be presented before the BioInnovation Panel. The BioInnovation panel’s role is to provide guidance and suggestions in the form of an interactive discussion. The audience will at first observe and then join in the Q and A and application discussion.

Get the latest event updates

Take a Tour of BPI US West

See why attendees choose BioProcess International US West as #1 event choice to gain the science, technologies and contacts needed to accelerate promising biologics towards commercial success.